# the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia

> **NCT05864170** · EARLY_PHASE1 · RECRUITING · sponsor: **Shenzhen Hemogen** · enrollment: 3 (estimated)

## Conditions studied

- β-thalassemia

## Interventions

- **BIOLOGICAL:** β-globin restored autologous hematopoietic stem cells

## Key facts

- **NCT ID:** NCT05864170
- **Lead sponsor:** Shenzhen Hemogen
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-27
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 3 (ESTIMATED)
- **Last updated:** 2024-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05864170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05864170, "the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05864170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*